邦顺制药赴港IPO 商业化收入近乎为0 平均每天烧掉65万元

Group 1 - The core asset of Bangshun Pharmaceutical is Bezeqixitini, which is used for the treatment of myelofibrosis [2] - In 2024, Bangshun Pharmaceutical is projected to achieve revenue of 943,000 yuan, while the revenue for the first nine months of 2025 is zero, primarily coming from technology transfers of preclinical projects [2] - The net loss for Bangshun Pharmaceutical in 2024 is approximately 88.44 million yuan, with the net loss for the first nine months of 2025 expanding to 179 million yuan, indicating a daily cash burn of 650,000 yuan [2] Group 2 - As of September 30, 2025, Bangshun Pharmaceutical has cash and cash equivalents of 158 million yuan, net liabilities of 575 million yuan, and net current liabilities of 652 million yuan [3] - The decision to list on the Hong Kong Stock Exchange coincides with a resurgence in biotech IPOs, with 26 biotech companies raising a total of 29.265 billion HKD in 2025, a significant year-on-year increase of 751.7% [3] - The market environment has shifted, with investors focusing more on clinical progress and commercialization capabilities rather than just the number of drug candidates [3]